Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Journal of Diabetes Investigation (2019) 10:760-770. https://doi.org/10.1111/jdi.12971
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2024
- Urheber
-
Kadowaki, Takashi
Nangaku, Masaomi
Hantel, Stefan
Okamura, Tomoo
von Eynatten, Maximilian
Wanner, Christoph
Koitka-Weber, Audrey
- DOI
-
10.1111/jdi.12971
- URN
-
urn:nbn:de:bvb:20-opus-325246
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kadowaki, Takashi
- Nangaku, Masaomi
- Hantel, Stefan
- Okamura, Tomoo
- von Eynatten, Maximilian
- Wanner, Christoph
- Koitka-Weber, Audrey
- Universität Würzburg
Entstanden
- 2024
Ähnliche Objekte (12)
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
Impact of Kidney Function on Cardiovascular Risk and Mortality: A Comparison of South Asian and European Cohorts
Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease
Anti-inflammatory potential of Empagliflozin
Empagliflozin: a potential anticancer drug
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
Impact of Kidney Function on Cardiovascular Risk and Mortality: A Comparison of South Asian and European Cohorts
Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease
Anti-inflammatory potential of Empagliflozin
Empagliflozin: a potential anticancer drug
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
Impact of Kidney Function on Cardiovascular Risk and Mortality: A Comparison of South Asian and European Cohorts
Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease
Anti-inflammatory potential of Empagliflozin